Conclusion: new parameters were found as predictors of moderate-severe mucositis.

EP-1036
Glotic carcinoma stage T1 radiotherapy
G. Dickie1, J. Askew2, L. Tripcony1, T. Ha1
1Royal Brisbane and Women’s Hospital - Cancer Care Centre, Department of Radiation Oncology, Brisbane, Australia
2Royal Brisbane and Women’s Hospital, ENT, Brisbane, Australia

Purpose or Objective: Retrospective review of results of radiotherapy for stage T1 glottic carcinoma.

Material and Methods: A retrospective review was done of all patients with squamous cell carcinoma of the glottis stage T1 treated with radiotherapy between 1960 and 2012 inclusive. There were 995 patients identified. All patients were treated with wedged lateral or angled anterior oblique technique. The main site of relapse was local and hence the main end point for analysis was local control at 5 years. Survival curves were calculated using Kaplan Meier method and log rank test used to comparer differences.

Results: Overall the 5 year freedom from relapse was 88%. The only factor which influenced outcome was time period of radiotherapy with those between 1960 and 1980 had a 84% relapse free rate, significantly worse than the latter time period. Other factors examined included sex, age, substage T1a and T1b, grade, radiation dose, radiation field size and duration of radiation, and none of those factors had a significant effect on outcome. There were 121 relapses, most in the primary alone and most within the first two years.

Conclusion: The overall 5 year freedom from relapse was 88%.

EP-1037
Dysphagia and irradiation of constrictor pharyngeal muscles: a clinical-dosimetric correlation

1Fondazione di Ricerca e Cura “Giovanni Paolo II”- Catholic University of Sacred Heart, Radiation Oncology Unit, Campobasso, Italy
2Fondazione di Ricerca e Cura “Giovanni Paolo II”- Catholic University of Sacred Heart, Radiation Oncology Unit, Campobasso, Italy
3Fondazione di Ricerca e Cura “Giovanni Paolo II”- Catholic University of Sacred Heart, Medical Physics Unit, Campobasso, Italy
4Fondazione di Ricerca e Cura “Giovanni Paolo II”- Catholic University of Sacred Heart, Radiology Unit, Campobasso, Italy
5Fondazione di Ricerca e Cura “Giovanni Paolo II”- Catholic University of Sacred Heart, Department of Radiotherapy, Rome, Italy

Purpose or Objective: To correlate clinical late dysphagia with the dose received by the constrictor pharyngeal muscles in patients receiving induction chemotherapy (ICT) and radiochemotherapy (RT-CT) with SIB-VMAT technique.

Material and Methods: Between July 2010 and January 2015, 51 patients with locally advanced head and neck cancer underwent ICT and subsequent RT-CT with concurrent weekly Cisplatin. The superior, middle, and inferior (S, M, and I) pharyngeal constrictors muscles (CM) were delineated and the correlation between dosimetric parameters and late pharyngeal toxicity was analyzed.

Results: 51 patients [M/F: 41/10, median age 56, range 30-77, stage III: 10 (20%), stage IV: 41 (80%)] were included in this analysis. The tumor site was: oropharynx in 21 (40%) patients, epipharynx in 10 (20%), oral cavity in 9 (18%), larynx in 5 (10%), and hypopharynx in 6 (12%). ICT in the majority of cases (74%), was based on Cisplatin - 5 -Fluourouracil, with the addition of Docetaxel in 26% of cases. The dose delivered to the primary tumor was 67.5 Gy (in 8 patients, 16 %) and 70.5 Gy (in 43 patients, 84 %); 60 Gy and 55.5 Gy were delivered on high and low risk lymph node levels, in 30 fractions with SIB-VMAT (2 arcs) technique, respectively. With a median follow-up of 11 months (range 3-44), late G1 dysphagia was recorded in 6 patients (12%) and late G2 dysphagia was observed in 2 patients (4%) (CTC-AE v. 4.3). Other late toxicities are reported in the Table 1. G3-4 toxicities were not recorded. In DVH analysis, the median dose received by CM was 66.2 Gy (S: 67.4 Gy, M and I: 67.2 Gy), with V50 being 96.9 %: 97.4%, M: 98.3%, and I: 95.9 %, and V60 being 82.4%: 86.8%, M: 90.1, and I: 73.8%. The median dose received by the larynx was 63.5 Gy (V50: 94.1 %, and V60: 66.2 %). No statistically significant difference between the group of patients with and without late dysphagia was observed.

Table 1: Late toxicity (CTC - AB v. 4.3)

<table>
<thead>
<tr>
<th>Go</th>
<th>G1</th>
<th>G2</th>
<th>G3</th>
<th>G4</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 (0)</td>
<td>9 (8)</td>
<td>1 (2)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>0 (0)</td>
<td>16 (3)</td>
<td>5 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>0 (0)</td>
<td>8 (16)</td>
<td>1 (2)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

Conclusion: No statistically significant correlation between dose delivered to the constrictors muscles and late dysphagia was observed in this patients cohort. This result may depend on tolerability of the treatment and then by the small number of recorded adverse events.

EP-1038
IMRT/VMAT-SIB technique chemoradiation in locally advanced head and neck cancer: toxicity results

1Fondazione di Ricerca e Cura “Giovanni Paolo II”- Catholic University of Sacred Heart, Radiation Oncology Unit, Campobasso, Italy
2Fondazione di Ricerca e Cura “Giovanni Paolo II”- Catholic University of Sacred Heart, Medical Physics Unit, Campobasso, Italy
3Fondazione di Ricerca e Cura “Giovanni Paolo II”- Catholic University of Sacred Heart, Radiology Unit, Campobasso, Italy
4Fondazione di Ricerca e Cura “Giovanni Paolo II”- Catholic University of Sacred Heart, Department of Radiotherapy, Rome, Italy

Purpose or Objective: To evaluate the toxicity of intensity modulated radio-chemotherapy with simultaneous integrated boost technique (SIB) after induction chemotherapy in patients with locally advanced head and neck (H&N) cancer.

Material and Methods: The IRMA studies are described in the table. Patients with stage III-IV H&N cancer, without progressive disease after induction chemotherapy (IC), underwent radio-chemotherapy with weekly Cisplatin 30